Cost effectiveness of left atrial appendage closure with the Watchman device for atrial fibrillation patients with absolute contraindications to warfarin

Europace

Volumn 18, Issue 7, 2016, Pages 979-986

  Reddy, Vivek Y ^a   Akehurst, Ronald L ^b   Armstrong, Shannon O ^c   Amorosi, Stacey L ^d   Brereton, Nic ^e   Hertz, Deanna S ^c   Holmes, David R ^f  

^a MOUNT SINAI MEDICAL CENTER   (United States)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

^c GfK Bridgehead   (United States)

^d BOSTON SCIENTIFIC CORPORATION   (United States)

^e BRESMED   (United Kingdom)

^f MAYO CLINIC   (United States)

Author keywords

Apixaban; Contraindicated; Cost effectiveness analysis; Left atrial appendage closure; Stroke prevention; Watchman

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; APIXABAN; CLOPIDOGREL; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE; TICLOPIDINE; WARFARIN;

ANALOGS AND DERIVATIVES; ATRIAL FIBRILLATION; CONTRAINDICATIONS; COST BENEFIT ANALYSIS; DEVICES; ECONOMICS; GERMANY; HEART ATRIUM APPENDAGE; HEART SURGERY; HUMAN; MARKOV CHAIN; PATHOPHYSIOLOGY; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; STROKE; SURGERY; THEORETICAL MODEL; TIME FACTOR; TREATMENT OUTCOME;

ANTICOAGULANTS; ASPIRIN; ATRIAL APPENDAGE; ATRIAL FIBRILLATION; CARDIAC SURGICAL PROCEDURES; COST-BENEFIT ANALYSIS; GERMANY; HUMANS; MARKOV CHAINS; MODELS, THEORETICAL; PYRAZOLES; PYRIDONES; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; STROKE; TICLOPIDINE; TIME FACTORS; TREATMENT OUTCOME; WARFARIN;

EID: 84975484131     PISSN: 10995129     EISSN: 15322092     Source Type: Journal    
DOI: 10.1093/europace/euv412     Document Type: Article

References (40)

1. Brüggenjürgen B, Reinhold T, McBride D, Willich SN. Atrial fibrillation-epidemiologic, economic and individual burden of disease. Dtsch Med Wochenschr 2010;135: 521-5.
2. Holmes DR. Atrial fibrillation and stroke management: Present and future. Seminars in Neurology 2010;30:528-36.
3. Tu HT, Campbell BC, Christensen S, Collins M, De Silva DA, Butcher KS et al. Pathophysiological determinants of worse stroke outcome in atrial fibrillation. Cerebrovasc Dis 2010;30:389-95.
4. Avesum A, Csiba L, González-Zuelgaray J, Hankey GJ, Hoppe-Tichy T, Hu D et al. Atrial Fibrillation-Related Stroke: An Avoidable Burden. Strike Out Stroke in Atrial Fibrillation 2012. http://www.stopafib.org/downloads/News436-Avoidable.pdf (2 December 2015, date last accessed).
5. Camm JA, Lip GYH, De Caterina R, Savelieva I, Atar D, Hohnloser SH et al. 2012 focused update of the ESC guidelines for the management of atrial fibrillation. Eur Heart J 2012;33:2719-47.
6. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: Antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007;146: 857-67.
7. Hylek EM, Evans-Molina C, Shea C, Henault LE, Regan S. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation 2007;115:2689-96.
8. Go AS, Hylek EM, Borowsky LH, Phillips KA, Selby JV, Singer DE. Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: The Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. Ann Intern Med 1999;131: 927-34.
9. The ACTIVE Investigators. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med 2009;360:2066-78.
10. Connolly SJ, Eikelbloom J, Joyner C, Diener HC, Hart R, Golitsyn S et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011;364:806-17.
11. Holmes DR, Reddy VY, Turi ZG, Doshi SK, Sievert H, Buchbinder M et al. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: A randomized non-inferiority trial. Lancet 2009;374:534-42.
12. Blackshear JL, Odell JA. Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation. Ann Thorac Surg 1996;61:755-9.
13. Reddy VY, Mobius-Winkler S, Miller MA, Neuzil P, Schuler G, Wiebe J et al. Left atrial appendage closure with theWatchman Device in patients with a contraindication for oral anticoagulation: The ASAP study (ASA Plavix feasibility study with Watchman left atrial appendage closure technology). J Am Coll Cardiol 2013;61: 2551-6.
14. National Institute for Health and Clinical Excellence. Single Technology Appraisal: Dabigatran. Specification for Manufacturer/Sponsor Submission of Evidence. London: National Institute for Health and Clinical Excellence; 2009.
15. The ACTIVE Investigators. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events (ACTIVE W): A randomised controlled trial. Lancet 2006; 367:1903-12.
16. Gage BF, vanWalraven C, Pearce L, Hart RG, Koudstaal PJ, Boode BS et al. Selecting patients with atrial fibrillation for anticoagulation: Stroke risk stratification in patients taking aspirin. Circulation 2004;110:2287-92.
17. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel userfriendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: The Euro Heart Survey. Chest 2010;138:1093-100.
18. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Arch Intern Med 1994;154:1449-57.
19. Ariesen MJ, Claus SP, Rinkel GJE, Algra A. Risk factors for intracerebral hemorrhage in the general population. Stroke 2003;34:2060-6.
20. Stroke Prevention in Atrial Fibrillation Investigators. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke prevention in atrial fibrillation III randomised clinical trial. Lancet 1996;348:633-8.
21. Sub-group analysis of PROTECT-AF data. Data on file with Boston Scientific, April 2013.
22. Sterbetafel 2006/2008 Deutschland, Statistisches Bundesamt, Wiesbaden, 2009. http://www.lifetable.de/cgi-bin/Country.plxCountry=Germany (27 January 2012, date last accessed).
23. Gage BF, Cardinalli AB, Owens DK. The effect of stroke and stroke prophylaxis with aspirin or warfarin on quality of life. Arch Intern Med 1996;156:1829-36.
24. Lee S, Anglade MW, Meng J, Hagstrom K, Kluger J, Coleman CI. Cost-effectiveness of apixaban compared with aspirin for stroke prevention in atrial fibrillation among patients unsuitable for warfarin. Circ Cardiovasc Qual Outcomes 2012;5:472-9.
25. Lee S, Mullin R, Blazawski J, Coleman CI. Cost-effectiveness of apixaban compared with warfarin for stroke prevention in atrial fibrillation. PLoS One 2012;7:e47473.
26. Pink JP, Lane S, Pirmohamed M, Hughes SA. Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: Quantitative benefit-harm and economic analyses. BMJ 2011;343:d6333.
27. Gage BF, Cardinalli AB, AlbersGW, Owens DK. Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation. JAMA 1995;274:1839-45.
28. Sullivan PW, Lawrence W, Ghuschcyan V. A national catalog of preference-based scores for chronic conditions in the United States. Medical Care 2005;43:736-49.
29. Szende A, Williams A. Measuring Self-Reported Population Health: An International Perspective based on EQ-5D. EuroQol Group 2004. http://www.euroqol.org/fileadmin/userupload/Documenten/PDF/Books/MeasuringSelf-Reported PopulationHealth-AnInternationalPerspectivebasedonEQ-5D.pdf (15 January 2014, date last accessed).
30. Sullivan PW, Arant TW, Ellis SL, Ulrich H. The cost effectiveness of anticoagulation management services for patients with atrial fibrillation and at high risk of stroke in the US. Pharmacoeconomics 2006;24:1021-33.
31. German Institute for Hospital Remuneration System (InEK). G-DRG System. 2014. http://www.g-drg.de/(1 March 2014, date last accessed).
32. German pharmaceutical pricing. From Lauer Fischer. http://www.lauer-fischer.de/LF/Seiten/Verwaltung/Kundencenter.aspx (1 March 2014, date last accessed).
33. Scheuringer M, Sahakyan N, Krobot K, Ulrich V. Cost of clinical event in health economic evaluations in Germany: A systematic review. Cost Eff Resour Alloc 2012;10:7.
34. McBride D, Mattenklotz AM, Willich SN, Brüggenjürgen B. The costs of care in atrial fibrillation and the effect of treatment modalities in Germany. Value Health 2009;12:293-301.
35. Ward A, Payne A, Caro JJ, Heuschmann PU, Kolominsky-Rabas PL. Care needs and economic consequence after acute ischemic stroke: The Erlanger Stroke Project. Euro J Neurol 2005;12:264-7.
36. Briggs AH, Ades AE, Price MJ. Probabilistic sensitivity analysis for decision trees with multiple branches: Use of the dirichlet distribution in a Bayesian framework. Med Decis Making 2003;23:341-50.
37. NICE. Social Value Judgments: Principles for the Development of NICE Guidance, 2nd ed. London, UK: The National Institute for Health and Clinical Excellence; 2008. http://www.nice.org.uk/Media/Default/About/what-we-do/Research-and-development/Social-Value-Judgements-principles-for-the-development-of-NICE-guidance.pdf (14 March 2014, date last accessed).
38. Helgason CM, Do MA, Nutescu E.Warfarin in patients with stroke and reasons for discontinuation. J Stroke Cerebrovasc Dis 2004;13:70-3.
39. Meschia JF, Bushnell C, Boden-Albala B, Braun LT, Bravata DM, Chaturvedi S et al. Guidelines for the primary prevention of stroke: A statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2014;45:3754-832.
40. Meier B, Blaauw Y, Khattab AA, Lewalter T, Sievert H, Tondo C et al. EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion. Europace 2014;16:1397-416.